Roger Sidhu
Overview
Explore the profile of Roger Sidhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moslemian A, Sidhu R, Roessler P, Wood R, Degen R, Getgood A, et al.
J Biomech
. 2020 Dec;
115:110133.
PMID: 33257006
Clinical outcomes following posterior cruciate ligament (PCL) reconstruction are often suboptimal. A better understanding of the biomechanical contributions of the PCL to knee stability under physiologic, clinically-relevant loading conditions could...
2.
Catenacci D, Tebbutt N, Davidenko I, Murad A, Al-Batran S, Ilson D, et al.
Lancet Oncol
. 2017 Sep;
18(11):1467-1482.
PMID: 28958504
Background: Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy, safety, and pharmacokinetics...
3.
Peeters M, Oliner K, Price T, Cervantes A, Sobrero A, Ducreux M, et al.
Clin Cancer Res
. 2015 Sep;
21(24):5469-79.
PMID: 26341920
Purpose: We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil,...
4.
Hecht J, Douillard J, Schwartzberg L, Grothey A, Kopetz S, Rong A, et al.
Cancer Treat Rev
. 2015 Jul;
41(8):653-9.
PMID: 26220150
RAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3,...
5.
Price T, Peeters M, Ruff P, Murugappan S, Sidhu R
Lancet Oncol
. 2014 Jul;
15(8):e303.
PMID: 24988928
No abstract available.
6.
Price T, Peeters M, Kim T, Li J, Cascinu S, Ruff P, et al.
Lancet Oncol
. 2014 Apr;
15(6):569-79.
PMID: 24739896
Background: The anti-EGFR monoclonal antibodies panitumumab and cetuximab are effective in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. We assessed the efficacy and toxicity of panitumumab versus...
7.
Douillard J, Rong A, Sidhu R
N Engl J Med
. 2013 Nov;
369(22):2159-60.
PMID: 24283232
No abstract available.
8.
Douillard J, Oliner K, Siena S, Tabernero J, Burkes R, Barugel M, et al.
N Engl J Med
. 2013 Sep;
369(11):1023-34.
PMID: 24024839
Background: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be...
9.
Sidhu R, Rong A, Dahlberg S
Clin Cancer Res
. 2013 Jan;
19(5):969-76.
PMID: 23303214
Pooled analyses of chemotherapy trials in metastatic colorectal cancer (mCRC) have suggested that progression-free survival (PFS) is a surrogate endpoint for overall survival (OS). However, this has not been evaluated...
10.
Evans R, Dueck G, Sidhu R, Ghosh S, Toman I, Loree J, et al.
Leuk Res
. 2011 Aug;
35(12):1637-43.
PMID: 21816470
The amplified myeloma centrosome has been identified as a therapeutic target. The present study explored the expression and prognostic significance of the centrosome-associated protein PLK1 in myeloma and the effect...